A number of other equities analysts have also recently commented on LIVN. Needham & Company LLC reduced their price objective on shares of LivaNova from $106.00 to $88.00 and set a “buy” rating for the company in a research report on Thursday, August 4th. The Goldman Sachs Group decreased their price target on shares of LivaNova from $85.00 to $73.00 and set a “buy” rating on the stock in a research note on Tuesday, August 16th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, LivaNova presently has a consensus rating of “Buy” and an average price target of $90.20.
LivaNova Stock Up 2.2 %
Shares of LIVN stock opened at $57.72 on Friday. LivaNova has a 52-week low of $53.28 and a 52-week high of $93.89. The stock has a market cap of $3.08 billion, a price-to-earnings ratio of -103.07 and a beta of 0.91. The firm’s 50-day moving average is $61.25 and its 200-day moving average is $68.66. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.47 and a current ratio of 2.93.
Hedge Funds Weigh In On LivaNova
Several institutional investors and hedge funds have recently modified their holdings of the business. Legal & General Group Plc raised its stake in LivaNova by 1.7% in the 2nd quarter. Legal & General Group Plc now owns 132,036 shares of the company’s stock worth $8,248,000 after purchasing an additional 2,187 shares in the last quarter. Nomura Holdings Inc. acquired a new position in LivaNova in the 2nd quarter valued at $897,000. Price T Rowe Associates Inc. MD lifted its position in shares of LivaNova by 1.1% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 28,970 shares of the company’s stock valued at $1,810,000 after acquiring an additional 308 shares during the period. State Street Corp grew its holdings in shares of LivaNova by 0.8% during the 2nd quarter. State Street Corp now owns 2,393,881 shares of the company’s stock worth $149,546,000 after purchasing an additional 18,634 shares in the last quarter. Finally, Clearline Capital LP bought a new position in shares of LivaNova in the second quarter worth $438,000. 98.89% of the stock is currently owned by institutional investors and hedge funds.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
- Get a free copy of the StockNews.com research report on LivaNova (LIVN)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.